After it was approved in 2019, Spravato, a depression treatment derived from the club drug ketamine, was looking like a dud. But recently it has taken off, and it surpassed $1 billion in annual sales last year for its maker, Johnson and Johnson.
Further Listening:
-A Lawyer Says He Doesn't Need Help for Psychosis. His Family Disagrees.
-America's Maternal Mental Health Crisis
Further Reading:
-J&J’s Ketamine-Derived Drug Is Taking Off
-Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.
Learn more about your ad choices. Visit megaphone.fm/adchoices
